INC Research Holdings, Inc. (INCR) traded higher in the last at $53.65, gaining 0.65 points or 1.23%. From the data available, it can be said that the stock did not make an impact in the money flow department with the net figure coming to be $(-3.79) million. The composite uptick value of $4.6 million was eclipsed by the accrued downtick value of $8.39 million, thereby ensuring the up/down ratio of 0.55. For the week, the shares have posted returns of 3.07%.A block trade registered during the day has revealed $1.05 million in upticks and $5.36 million in downticks. The up/down ratio in this case turned out to be 0.2. The net money flow for the block trade was $(-4.31) million.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of INC Research Holdings, Inc. rose by 3.97% in the last five trading days and 2.19% for the last 4 weeks. INC Research Holdings, Inc. is up 17.61% in the last 3-month period. Year-to-Date the stock performance stands at 2.19%. INC Research Holdings, Inc. (NASDAQ:INCR) rose 1.42% or 0.75 points on Wednesday and made its way into the gainers of the day. After trading began at $53.25 the stock was seen hitting $54.4 as a peak level and $52.95 as the lowest level. The stock ended up at $53.75. The daily volume was measured at 598,026 shares. The 52-week high of the share price is $57.11 and the 52-week low is $34.19. The company has a market cap of $2,882 million.
Company has reported several Insider transactions to the SEC, on Jan 23, 2017, Alistair Macdonald (Chief Executive Officer) sold 1,375 shares at 50.50 per share price.On Jan 23, 2017, Gregory S Rush (Executive VP and CFO) sold 2,907 shares at 50.58 per share price.On Jan 23, 2017, Christopher L Gaenzle (CAO, GC & Sec) sold 1,186 shares at 50.09 per share price.
INC Research Holdings Inc Last issued its quarterly earnings results on Oct 31, 2016. The company reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $0.63. The company had revenue of $259.56 million for the quarter, compared to analysts expectations of $259.68 million. The companys revenue was up 10.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.58 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.INC Research Holdings Inc was Initiated by First Analysis Sec on Dec 20, 2016 to Equal-Weight, Price Target of the shares are set at $59.
INC Research Holdings, Inc. is a global contract research organization. It provides the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Its services include clinical trial management services comprising patient recruitment and retention, project management, clinical monitoring, drug safety/pharmacovigilance, medical affairs, quality assurance, regulatory and medical writing, and functional service; and data services consisting of clinical data management, electronic data capture, and biostatistics. INC Research Holdings, Inc. is headquartered in Raleigh, North Carolina.